The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas.
Michael Crump
Research Funding - MethylGene
Charalambos Andreadis
Research Funding - MethylGene
Sarit E. Assouline
Research Funding - MethylGene
David Rizzieri
Research Funding - MethylGene
Amanda Copeland
Research Funding - MethylGene
Richard H. C. Van Der Jagt
Research Funding - MethylGene
Susan Fox
Research Funding - MethylGene
Gregory K. Reid
Employment or Leadership Position - MethylGene
Jeffrey M. Besterman
Employment or Leadership Position - MethylGene
Stock Ownership - MethylGene
Robert E. Martell
Stock Ownership - MethylGene
Research Funding - MethylGene
Anas Younes
Honoraria - MethylGene
Research Funding - MethylGene